Objetivo The aim of this project is to generate a comprehensive platform of intellectual property to facilitate the discovery and development of a new generation of therapeutics with the ability to activate or inhibit the c-Ret receptor tyrosine kinase. Mutations in c-Ret are directly implicated in human cancers, and the c-Ret ligand, GDNF, is being developed as a therapeutic agent for neurodegenerative disorders such as Parkinson's disease and ALS. To develop c-Ret as a target for drug discovery we propose: i) to validate c-Ret as a drug target; ii) to develop scaleable assays for high throughput screening of c-Ret inhibitors and activators; iii) to isolate artificial c-Ret peptide ligands; iv) to determine the 3D structures of the extracellular and kinase domains of wild type and oncogenic c-Ret; v) to identify ligand binding sites in the c-Ret extracellular domain. Our long-term goal is to enter into license agreements with interested user groups for the exploitation of the generated knowledge and technology platform. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesbiochemistrybiomoleculesnatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineneurologyparkinson Programa(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Tema(s) 1.1.1.-3. - Key action The "Cell factory" Convocatoria de propuestas Data not available Régimen de financiación CSC - Cost-sharing contracts Coordinador KAROLINSKA INSTITUTE Aportación de la UE Sin datos Dirección Retzius vaeg 8 171 77 STOCKHOLM Suecia Ver en el mapa Coste total Sin datos Participantes (3) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo AUGUST KIRCHENSTEIN INSTITUTE OF MICROBIOLOGY AND VIROLOGY Letonia Aportación de la UE Sin datos Dirección Ratsupites 1 1067 RIGA Ver en el mapa Coste total Sin datos CANCER RESEARCH UK Reino Unido Aportación de la UE Sin datos Dirección Lincoln's Inn Field 61 WC2A 3PX LONDON Ver en el mapa Coste total Sin datos XERION PHARMACEUTICALS GMBH Alemania Aportación de la UE Sin datos Dirección Fraunhoferstrasse 9 82152 PLANEGG / KRAILLING Ver en el mapa Coste total Sin datos
